Octopus Eclipse VCT plc : Publication of a Prospectus and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Octopus Eclipse VCT plc : Publication of a Prospectus and Circulars in respect of proposals to merger with Octopus Apollo VCT plc and an Offer for Subscription by Octopus Apollo VCT plc

Octopus Apollo VCT plc ("Apollo") Octopus Eclipse VCT plc ("Eclipse") 

(together the "Companies")

4 November 2016

Publication of a Prospectus (the "Prospectus") and Circulars (the "Circulars") in connection with recommended proposals to merge the Companies (to be completed pursuant to a scheme of reconstruction (the "Scheme" or "Merger") under section 110 Insolvency Act 1986) and an offer for subscription by Apollo.  

On 27 September 2016, the boards of Apollo and Eclipse (the "Boards") announced that they had entered into discussions to merge the Companies into one company (the "Enlarged Company") and the Apollo Board announced that it also intended to raise further funds into Apollo pursuant to an offer for subscription (the "Offer"). The Boards are pleased to advise that discussions have now concluded and that the Companies have today issued the Circulars to set out the proposals for the Merger for consideration by their respective shareholders and that Apollo has issued a Prospectus relating to the Offer and Merger. The Companies have similar investment mandates and are both managed by Octopus Investments Limited ("Octopus").

The Offer

Apollo is seeking to raise £20 million under the Offer, which is subject to the approval of the Apollo shareholders. The expected timetable for the Offer is set out below.

The Scheme

The Merger is expected to deliver a number of additional benefits to shareholders including:

  • participation in a larger VCT with a more diversified portfolio, thereby spreading the portfolio risk across a broader range of investments;
  • efficiencies in annual running costs and administration for the Enlarged Company compared to the separate companies;
  • enhancing the ability of the Enlarged Company to find high quality new investments, raise funds, as well as pay dividends and support buybacks in the future.

The mechanism by which the Merger will be completed is as follows:

  • Eclipse will be placed into members' voluntary liquidation pursuant to a scheme of reconstruction under Section 110 IA 1986; and
  • all of the assets and liabilities of Eclipse will be transferred to the Company in consideration for the issue of Scheme Shares.

The Scheme will be completed on a relative unaudited net asset value basis, adjusted for the anticipated costs of the Scheme, based on the latest unaudited valuations of the Companies' investments. An accounting firm will review the latest unaudited net asset values of the Companies and valuations of the Companies' investments prior to the Merger becoming effective and will confirm that they have been prepared in accordance with similar principles as would have been used in producing year end accounts. The effect of the Scheme will be that the Eclipse shareholders will receive Apollo shares with the same total net asset value as their Eclipse shares.

The Scheme is conditional upon its approval by the Apollo shareholders and by the Eclipse shareholders, as well as the other conditions set out in the Prospectus and Circulars.

As the Companies have a similar investment objective and policy, the same investment manager and other common advisers, the proposed Merger should be achievable without major additional cost or disruption to the Companies and their combined portfolio of investments.

The aggregate anticipated cost of undertaking the Merger is approximately £331,000, including VAT, legal and professional fees, stamp duty and the costs of winding up Eclipse. The costs of the Merger will be split proportionately between the Companies by reference to their respective net asset values immediately prior to the Merger.

Shareholders and investors should note that the merger by way of the Scheme will be outside the provisions of the City Code on Takeovers and Mergers.

The portfolio of assets which will be transferred from Eclipse to the Company as part of the Scheme is considered to be in keeping with Apollo's investment policy. The extent of the liabilities (if any) which will be transferred from Eclipse to Apollo as part of the Scheme will be those which are incurred in the ordinary course of business and merger costs which remain unpaid at the time of transfer. Any such liabilities are expected to be nominal in comparison to the value of the assets.

Eclipse shareholders who do not vote in favour of the Resolution to be proposed at Eclipse's first general meeting, as referred to in the timetable below, are entitled to dissent and have their shareholding purchased by the liquidators of Eclipse (the "Liquidators") at a price agreed between the dissenting Eclipse shareholders and the Liquidators (or by arbitration), which would be expected to be at a significant discount to the net asset value of an Eclipse share. If the conditions of the Scheme are not satisfied, the Companies will continue in their current form and the Boards will continue to review all options available to them regarding the future of the Companies.

Clearance has been requested from HMRC that the Scheme meets the requirements of the Merger Regulations and, therefore, that the implementation of the Scheme should not affect the status of Apollo as a VCT. It is the intention of the Apollo Board to continue to comply with the requirements of ITA 2007 following the Merger so that Apollo continues to qualify as a VCT.

EXPECTED TIMETABLE, OFFER STATISTICS AND COSTS

Expected Timetable for the Scheme

Apollo

Latest time and date for receipt of Forms of Proxy for the General Meeting 2.30 pm on 8 December 2016
General Meeting 2.30 pm on 12 December 2016
Scheme Calculation Date after 5.00 pm on 16 December 2016
Scheme Effective Date for the transfer of the assets and liabilities of Eclipse to the Company and the issue of Scheme Shares 19 December 2016
Announcement of the results of the Scheme 19 December 2016
Admission of, and dealings in, Scheme Shares issued to commence 20 December 2016
CREST accounts credited (if applicable) 20 December 2016 2016
Certificates for Scheme Shares despatched to Eclipse Shareholders Week commencing 9 January 2017

Eclipse

Latest time for receipt of forms of proxy for the Eclipse First General Meeting   2.30 pm on 5 December 2016
Eclipse First General Meeting   2.30 pm on 7 December 2016
Latest time for receipt of forms of proxy for the Eclipse Second General Meeting   10.30 am on 15 December 2016  
Final expected date of trading of the Eclipse Shares 16 December 2016
Scheme Record Date for Eclipse Shareholders' entitlements under the Scheme 5.00 pm on 16 December 2016
Scheme Calculation Date after 5.00 pm on 16 December 2016
Dealings in Eclipse Shares suspended* 7.30 am on 19 December 2016
Eclipse register of members closed 9.30 am on 19 December 2016
  Eclipse Second General Meeting     10.30 am on 19 December 2016  
Scheme Effective Date for the transfer of the assets and liabilities of Eclipse to the Company and the issue of Scheme Shares 19 December 2016  
Announcement of the results of the Scheme 19 December 2016  
Cancellation of the Eclipse Shares' listing 8.00 am on 20 December 2016  

(*The final expected date of trading of the Eclipse shares will be 16 December 2016. See the timetable for Apollo with regard to admission, CREST accounts being credited and certificates being despatched in respect of the Scheme Shares)

Expected Timetable for the Offer

Launch date of the Offer 4 November 2016  
Deadline for receipt of applications for first allotment 9.00 am on 5 January 2017
First allotments under the Offer 6 January 2017
Deadline for receipt of applications for final allotment in 2016/17 tax year 12 noon on 5 April 2017
Deadline for receipt of applications for final allotment in 2017/18 tax year 12 noon on 3 November 2017
Closing date of the Offer 12 noon on 3 November 2017

             

  • The Offer will close earlier if fully subscribed. The Apollo Board reserves the right to close the Offer earlier and to accept applications and issue ordinary shares under the Offer ("Offer Shares") at any time following the receipt of valid applications.  
  • The results of the Offer will be announced to the London Stock Exchange through a Regulatory Information Service provider authorised by the Financial Conduct Authority.  
  • Dealing is expected to commence in Offer Shares within ten business days of allotments and share and tax certificates are expected to be despatched within 14 business days of allotments.  
  • The dates set out in the expected timetable above may be adjusted by Apollo, in which event details of the new dates will be notified through a Regulatory Information Service.

Offer Statistics

Costs of Offer Up to 7.5% of gross proceeds of Offer
Initial adviser charge or intermediary commission Up to 4.5% of gross proceeds of Offer
Ongoing adviser charge or annual ongoing charge Up to 0.5% per annum of the latest NAV of gross sums invested in the Offer for up to 9 years
  • The cost of the Offer is capped at 7.5%. Octopus has agreed to indemnify Apollo against the costs of the Offer in excess of this amount.

Related Party Transaction

In connection with the Offer, Octopus will receive a fee of up to 5.5% of the gross proceeds received by Apollo under the Offer (comprising an initial charge of 3.0% of the gross funds raised and an initial commission of up to 2.5% of gross funds raised from investors who have not invested their money through a financial intermediary ("Direct Investors")) and an additional ongoing charge of 0.5% of the net asset value of the investment amount received by Apollo from Direct Investors, payable for up to nine years, provided the Direct Investors continue to hold their Offer shares.

The above arrangement falls within Listing Rule 11.1.10 R.

Copies of the Prospectus and Circulars will shortly be available for inspection at the National Storage Mechanism, which is located at:

http://www.morningstar.co.uk/uk/NSM

and on the Company's website:

http://www.octopusinvestments.com

For further information please contact:

Nicola Board Company Secretary 0207 776 8663

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 165

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 58

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 153

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 63

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 148

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 239

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 247

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 211

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 89

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 410

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading

Top 5 Most Recently Viewed Articles

Verizon Secures $66 Million EIS Partnership with Coast Guard

Updated Category News Views 283

Verizon Awarded $66 Million Enterprise Infrastructure Solutions Contract In a significant development, Verizon Business has been awarded a substantial contract valued at up to $66 million by the U.S. Coast Guard. This eight-year Enterprise Infrastructure Solutions (EIS) task order represents a robust commitment to enhancing the Coast Guard's communication and operational...

Continue Reading
Icelandic Glacial Becomes Laver Cup 2025's Official Water

Updated Category News Views 168

Icelandic Glacial to Hydrate Laver Cup 2025 Attendees Icelandic Glacial™, recognized for its exceptional quality and purity, has been designated as the Official Water for the highly anticipated Laver Cup 2025. This prestigious tournament is scheduled to take place at the Chase Center, showcasing top-tier men's tennis. A Perfect Fit for a Grand Event Coming from the...

Continue Reading
Dick's Sporting Goods Shows Promise for Q3 Amid Market Trends

Updated Category News Views 196

Dick's Sporting Goods Anticipates Strong Q3 Results Dick's Sporting Goods Inc. (NYSE: DKS) is gearing up for its fiscal third-quarter earnings report, creating buzz among investors eager to understand how the retailer is managing consumer demand and its recent strategic moves. As the company prepares to disclose its earnings, the market remains cautiously optimistic,...

Continue Reading
HyOrc Corporation Charts New Path with Green Fuel Innovations

Updated Category News Views 165

HyOrc Corporation's Strategic Market Transformation HyOrc Corporation (OTCID: HYOR) is making significant strides in the clean energy sector with a recent change in its trading symbol on the OTC markets. This evolution reflects not only a fresh identity but also the dynamic advancements the company is achieving in green fuel technologies and hydrogen mobility....

Continue Reading
Exploring Nature Through Art: BlackBook's New Exhibition

Updated Category News Views 227

BlackBook Presents Unveils a Unique Art Exhibition BlackBook Presents is set to embark on an exciting journey with its upcoming art exhibition titled Mother Nature in the Bardo. This innovative presentation, in collaboration with UNESCO's GEM Report, aims to foster meaningful discussions about art, culture, and their profound connection to environmental issues. Through an...

Continue Reading